严重急性呼吸综合征冠状病毒2疫苗在胸部肿瘤患者中的疗效:一项支持对两剂疫苗后血清学反应微弱者接种第三剂的前瞻性研究
这项前瞻性疫苗监测研究纳入306例胸部肿瘤患者,中位年龄67.0岁,其中283例按28天间隔接种两剂BNT162b2 mRNA疫苗。第二剂后269例可评估血清学结果中17例(6.3%)仍为阴性,仅年龄(p<0.01)和长期糖皮质激素治疗(p=0.01)与免疫缺乏显著相关;30例接种第三剂后仅3例血清学持续阴性,其余明显血清阳转。作者结论认为SARS-CoV-2疫苗在胸部肿瘤患者中有效,多数在兩剂后获得免疫。
要点
- 306例胸部肿瘤患者接种BNT162b2 mRNA疫苗,283例完成两剂,中位随访6.7个月。
- 第二剂后269例可评估者中17例(6.3%)血清学仍阴性,34例(11%)抗体低于300任意单位/mL。
- 多因素分析仅年龄(p<0.01)与长期糖皮质激素治疗(p=0.01)与免疫缺乏显著相关。
核心结论
- 作者结论认为SARS-CoV-2疫苗在胸部肿瘤患者中有效,多数在兩剂后获得免疫;对1%持续低抗体滴度患者接种第三剂后免疫率为88%。
研究设计与样本
- 前瞻性疫苗监测研究,纳入306例胸部肿瘤患者,中位年龄67.0岁(四分位距58-74),其中283例按28天间隔接种两剂BNT162b2 mRNA疫苗。
- 采用Abbot Architect SARS-CoV-2免疫球蛋白G免疫分析法,于首剂前、第4周及第二剂后2至16周检测SARS-CoV-2刺突抗体。
主要发现
- 中位随访6.7个月,8例患者(2.6%)发生确诊的症状性SARS-CoV-2感染,病情迅速好转。
- 第二剂后14天以上可评估的269例血清学结果中,17例(6.3%)仍为阴性(<50任意单位/mL),34例(11%)低于300任意单位/mL(第12.5百分位)。
- 多因素分析中,仅年龄(p<0.01)和长期糖皮质激素治疗(p=0.01)与免疫缺乏显著相关。
- 共30例患者接种第三剂疫苗,此后仅3例血清学持续阴性,其余出现明显血清阳转。
临床怎么用
- 作者结论认为SARS-CoV-2疫苗在胸部肿瘤患者中有效,多数在兩剂后获得免疫;对1%持续低抗体滴度患者接种第三剂后免疫率为88%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer. METHODS: SARS-CoV-2-spike antibodies were measured using the Abbot Architect SARS-CoV-2 immunoglobulin G immunoassay before the first injection of BNT162b2 mRNA vaccine, at week 4, and 2 to 16 weeks after the second vaccine dose administration. The factors associated with antibody response were analyzed. RESULTS: Overall, 306 patients, with a median age of 67.0 years (interquartile range: 58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After a 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (<50 arbitrary units/mL, whereas 34 (11%) were less than 300 arbitrary units/mL (12.5th percentile). In multivariate analysis, only age (p < 0.01) and long-term corticosteroid treatment (p = 0.01) were significantly associated with a lack of immunization. A total of 30 patients received a third vaccine dose, with only three patients showing persistently negative serology thereafter, whereas the others exhibited clear seroconversion. CONCLUSIONS: SARS-CoV2 vaccines were found to be efficient in patients with thoracic cancer, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in an 88% immunization rate.
引用
- Gounant V, Ferré VM, Soussi G, et al. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. J Thorac Oncol. 2021. PMID: 34798306. doi:10.1016/j.jtho.2021.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。